instead, they state patients should discuss with their primary care physician and/or endocrinologist whether GLP-1 drug use should be ceased so that the risk of vision loss from NAION in their fellow eye is balanced with the hypoglycemic and cardiovascular benefits from treatment
Related: Navigating compounded GLP-1s safely After you reach your goal weight, the focus shifts from weight loss to long-term weight management
For many, GLP-1s deliver real benefits and sustained satisfaction
The TRIUMPH program includes multiple phase 3 trials, and one trial, TRIUMPH-Outcomes, is specifically designed to answer the question of whether retatrutide reduces major adverse cardiovascular events
Also available in a pack of 6
This consultative method works especially well for clients who are making new delivery systems or mix goods and need help figuring out how peptides behave in complicated matrices